Login / Signup

MicroRNA-193a-3p as a Valuable Biomarker for Discriminating between Colorectal Cancer and Colorectal Adenoma Patients.

Marija FabijanecAndrea Hulina-TomaškovićMario ŠtefanovićDonatella VerbanacIvana CelapAnita Somborac-BačuraMarija Grdić RajkovićAlma DemirovićSnjezana RamicBožo KrušlinLada RumoraAndrea ČeriMartha KoržinekJózsef PetrikNeven LjubičićNeven BaršićKarmela Barišić
Published in: International journal of molecular sciences (2024)
Specific markers for colorectal cancer (CRC), preceded by colorectal adenoma (pre-CRC), are lacking. This study aimed to investigate whether microRNAs (miR-19a-3p, miR-92a-3p, miR-193a-3p, and miR-210-3p) from tissues and exosomes are potential CRC biomarkers and compare them to existing biomarkers, namely carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9. MiRNA was isolated in the samples of 52 CRC and 76 pre-CRC patients. Expression levels were analyzed by RT-qPCR. When comparing pre-CRC and CRC tissue expression levels, only miR-193a-3p showed statistically significant result ( p < 0.0001). When comparing the tissues and exosomes of CRC samples, a statistically significant difference was found for miR-193a-3p ( p < 0.0001), miR-19a-3p ( p < 0.0001), miR-92a-3p ( p = 0.0212), and miR-210-3p ( p < 0.0001). A receiver-operating characteristic (ROC) curve and area under the ROC curve (AUC) were used to evaluate the diagnostic value of CEA, CA 19-9, and miRNAs. CEA and CA 19-9 had good diagnostic values (AUCs of 0.798 and 0.668). The diagnostic value only of miR-193a-3p was highlighted (AUC = 0.725). The final logistic regression model, in which we put a combination of CEA concentration and the miR-193a-3p expression level in tissues, showed that using these two markers can distinguish CRC and pre-CRC in 71.3% of cases (AUC = 0.823). MiR-193a-3p from tissues could be a potential CRC biomarker.
Keyphrases
  • end stage renal disease
  • poor prognosis
  • gene expression
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • stem cells
  • mesenchymal stem cells
  • risk assessment
  • climate change
  • bone marrow